The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Cardiome Pharma

Monday Deal Review: March 17, 2014

  Welcome to your Monday Biotech Deal Review for March 17, 2014, and happy St. Patrick’s day to the Irish (or Irish-for-a-day) among us!

This past week saw Patheon complete their plan of arrangement with JLL/Delta Patheon Holdings, wherein JLL/Delta acquired all outstanding shares of Patheon for US$9.32 cash a share. The 2 entities have now been amalgamated and will operate under Patheon Inc., with DSM Pharmaceutical Products also now combined with Patheon.

Read more of this post

Monday Deal Review: February 3, 2014

  Welcome to your Monday Biotech Deal Review for February 03, 2014!

This week saw Jamieson Labs complete the sale of their business to CCMP Capital Advisors, LLC.

In the commercial space, Sirona has executed licensing agreements with Obagi Medical Products and Wanbang Biopharmaceuticals in respect of  its patented skin lightening technology and its anti-diabetic SGLT2 inhibitor, respectively.   Regarding the Obagi agreement, Sirona will transfer its patented skin lightening technology and know-how to Obagi. Obagi will be responsible for the manufacturing, distribution and global sales of the final commercial products. Regarding the Wanbang license,  Sirona is transfering responsibility for all funding, clinical development, regulatory requirements, manufacturing, sales and marketing of its SGLT2 inhibitor in China for upfront and milestone payments of up to US$9.5M in addition to royalty payments.

For details and news on these deals, as well as the rest of the week’s major biotech news, hit the break.

Read more of this post

Monday Deal Review: November 25, 2013

  Welcome to your Monday Biotech Deal Review for November 25, 2013! This week saw Patheon enter into an agreement which will take the company private, once the necessary shareholder and court approval is obtained. Futher, Cardiome has closed its acquisition of Swiss-based Correvio in a cash and share deal. On the financing side of things, Aeterna Zentaris announced that it is seeking to raise US$13.7 million with its previosly announced public offering.

Hit the break the see the details on these deals, as well as the rest of the week’s major biotech news.

Read more of this post

Monday Deal Review: October 28, 2013

  Welcome to your Monday Biotech Deal Review for October 28, 2013! This week saw some activity in both the M&A and financing spaces, notably involving BELLUS Health, Concordia, Arch Biopartners, Novadaq and others.

Hit the break to catch up on the week’s major biotech news!

Read more of this post

Monday Deal Review: October 14, 2013

  Welcome to your Monday Biotech Deal Review for October 14, 2013!

Of particular note this week is the innovative collaboration between Sirona Biochem and Bloom Burton & Co. The venture seeks to develop and commercialize new therapeutics in the areas of inflammation and infectious disease. Such an arrangement purports to take advantage of Sirona’s proprietary fluorination technology platform, and Bloom Burton’s knowledge of the market and expertise in commercialization, delivering to market products targeted towards rare or neglected inflammatory diseases and bacterial resistance. This model shows significant promise, so look to this space to see how the relationship progresses.

Hit the break to get the full scoop on the week’s major stories!

Read more of this post

Monday Deal Review: October 7, 2013

  Welcome to your Monday Biotech Deal Review for October 7, 2013! A busy week saw significant activity in both the financing and commercial agreement spaces.  Of note is MedMira recieving a $6.1 million equity investment.

Hit the break for the full rundown of the week’s major biotech news! And thanks again to Jennifer Ng of Norton Rose Fulbright for helping out with this week’s post.

Read more of this post

Monday Deal Review: September 23, 2013

  Welcome to your Monday Biotech Deal Review for September 23, 2013! Now that we are in the full swing of September, the activity in the market has ramped up.

In terms of M&A, Axxess has purchased the assets of Revive Bioscience, including Revive’s product and IP portfolios, for an undisclosed amount. Easton has re-entered the drug market by purchasing rights in a female sexual arousal disorder drug. And MTPC has completed its acquisition of Medicago. Medicago’s shares are no longer listed as a result.

In terms of financing, IMRIS and Xylitol have both enetered into loan agreements. However, a number of other companies are also rasing capital through placements, including MedMira, Miraculins, and Bioniche .

Theres lots more to report, so hit the break to see the past weeks’ major biotech stories.

Once again, a big thank you to Jennifer Ng for her help in getting these stories to you.

Read more of this post

Monday Deal Review: August 19, 2013

Welcome to your Monday Biotech Deal Review for August 19, 2013! As August comes to a close, activity is beginning to pick up.  Bellus and Valeant have closed their acquisitions of Thallion and Bausch + Lomb, respectively.  On the financing side of things, Sophiris and Covalon are pursuing offerings, with Sophiris looking at rasing $65 million.  Finally, Transition, Vivione and Quest PharmaTech have executed deals for licensing or development.

Hit the break to see the whole story on these major deals and for the rest of the past weeks’ stories!

Read more of this post

Monday Deal Review: July 22, 2013

Welcome to your Monday Biotech Deal Review for July 22, 2013! A busy week saw acquisitions of Medicago by Mitsubishi Tanabe Pharma Corporation and Allon’s acquisition by Paladin Labs.

Hit the break to see the whole story on these major deals and for the rest of the past weeks’ stories!

Read more of this post

Monday Deal Review: July 8, 2013

Welcome to your Monday Biotech Deal Review for July 8, 2013! A busy two weeks has seen  lot of activity on the debt financing side of things. This includes Paladin and Bioniche’s complex debt financing and license arrangement.
Valeant’s ambitious financing push is also nering completion, with the public offering worth $2.3 billion closing and the nearly $3.3 billion in senior notes being priced.

Click through the break to see the full rundown of the past weeks’ stories!

Read more of this post

Monday Deal Review: April 8, 2013

Welcome to your Monday Biotech Deal Review for April 8, 2013! After a hiatus last week due to the holiday, this week we have a lot of activity to cover. Valeant, in particular has been quite busy, being forced to up their bid for Obagi to $24.00 in response to interest from Germany’s Merz Pharma Group. In addition, Valeant’s latest bid is already 70 percent more than Obagi’s average 20-day stock price before the takeover fight began, the highest premium for a U.S. drug-industry deal in four years, according to data compiled by Bloomberg. Further, the Royal Bank fo Canada has said Valeant could be willing to pay as much as $28 a share to top any new offer from Merz, pushing the premium to as high as 99 percent. Valeant has also begun an unrelated note exchange, and has separately engaged a generic manufacturer with a license agreement after Mylan’s regulatory approval of their own anti-viral acyclovir-containing Zovirax® ointment equivalent.

In other news, Stem Cell Therepuetics has signed their merger agreement with Trillium, based on negotiations with Trillium’s debentureholders. There is much more to cover, so follow the break to get up to date on the latest and biggest biotech stories.

Read more of this post

Valuation and other biotech mysteries – Part 6: The cost of developing a new drug

[Ed. This is the sixth part in Wayne’s series. You can access the whole thing by clicking here. Please leave comments or questions on the blog and Wayne will address them in future posts in this series.]

The Tufts Center for the Study of Drug Development has been the source of the most comprehensive studies of new drug developments, including costs, success rates and strategies. Their estimates include the cost of the failures and the lost income from simply investing in government bonds. Neither of these factors is relevant to our current discussion although the former is critical to the success of the industry.

The clinical development pathways for both Theratechnologies Inc. (TSX:TH) (NASDAQ: THER) and Oncolytics Biotech (TSX:ONC)(NASDAQ:ONCY) have been outlined in previous parts of this blog series  and it is appropriate to look at the expenses for these companies. The expenses of Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) in their development of both intravenous and oral forms of vernakalant are also shown below. The information for all three companies was found from their annual financial statements at www.sedar.com in about 30 minutes.

Read more of this post

2010 Canadian Healthcare Review: Success and Momentum Building

We had just finished the Q3 2010 report when I attended BioContact Québec in early October and the mood was discouraging. My co-author on these reports (James Smith, VP-Healthcare at Equicom) was in San Francisco in January for the annual JP Morgan conference and he described the overall mood as optimistic. What happened in those three months?

The subtitle for the 2010 Canadian Healthcare Review (pdf) is “Successes and Momentum Building.” The momentum building comes partially from the increased financing which occurred in Q4, and which appears to be continuing in 2011 – Bioniche’s Australian tranche and Paladin Labs’ bought deal.

The momentum also comes from the clinical and regulatory successes in 2010. Three novel products developed by Canadian companies were approved – Cardiome’s IV BRINAVESS (vernakalant), Theratechnologies’ EGRIFTA (tesamorelin), and one which we tend to forget because it was acquired by Medtronic in 2008 is CryoCath’s Arctic Front cryoablation system. Cipher and Labopharm also had specialty pharma products approved and many companies were successfully progressing products through Phase 2 and 3 clinical trials.

These successes are usually dwarfed by the failures but this was not the case in 2010. There were only two Phase 2 or 3 products for which development was terminated. There were three other products which had Phase 2 hiccups but for which product development is continuing. On balance, 2010 was a successful year for product development and regulatory approvals.

In any discussion of successes, we cannot forget the investors, who measure success by increases in share price. From a group of 105 companies we assessed, there were 17 companies with share price increases of 40% or more in 2010 (actually 18 as Nightingale Health Care should be added to the list). This is balanced by 32 companies which had share price decreases of 40% or more.

Success for the industry in 2011 will be defined by its clinical, regulatory and financing successes, and by share price performance of the companies. Some of the companies which made progress in 2010 with their Phase 2 and 3 clinical trials and regulatory filings will have data or decisions in 2011, while others will still be advancing their programs. If the industry is able to repeat the clinical and regulatory success rate of 2011, we expect that financing and share price performance will likely follow.

Monday Biotech “Happy Holidays” Deal Review: December 27, 2010

Welcome to your Monday Biotech “Happy Holidays” Deal Review!  For those who may have noticed, last week the Monday Biotech Deal Review took its own holiday, so this week’s digest contains biotech news spanning the past two weeks – to ensure you don’t miss a single drummer boy’s beat.  It has been a busy two weeks, with a notable $40M public offering by YM BioSciences of common shares that was announced, priced and closed, as well as an update by Angiotech with respect to its debt restructuring efforts.  There have also been some interesting strategic partnerships and licensing activity over the break.  Read on to learn more.     Read more of this post

Q3 Canadian Healthcare Review – Weakness Continues BUT Some Bright Spots

Data in the Q3 2010 Canadian Healthcare Review from the Equicom Group (co-authored by James Smith, Vice President Healthcare at Equicom and myself) shows a continuation of the weakness in biotech financing which we have seen in 2009 and 2010.

Bounceback From the Financial Crisis May Have Masked 2009 Weakness

While the level of funding seen during 2009 was a concern, the problem may have been partially hidden by the many large share price increases from lows they hit as a result of the financial crisis in late 2008. The level of funding in 2010 is lower and the impact of lower funding is now being seen in share price performance. Lower cash resources have resulted in lower activity levels and survival concerns, which has probably been a factor in the 40% or greater share price drop in the first 9 months of 2010 for 31 of 105 healthcare companies in the share price performance assessment. The bright spot is that investors can still make money in the sector, as 13 companies had their share prices increase by greater than 40% in that same period.

Protox and Oncolytics Start Q4 With a Bang

The $35 million dollar financing by Protox announced in September did not count in the Q3 total because the financing was not closed by September 30. The first $10 million tranche of that financing and the recent $25 million dollar bought deal financing by Oncolytics Biotech are a good start for Q4.

Pending Regulatory News May Build Buzz

There are also some upcoming events which could help create a little momentum in the sector. While Cardiome has had a delay in a U.S. Phase 3 study of its iv vernakalant (already approved in the E.U.), the start of Phase 3 trials of the oral version by its partner Merck would be a good boost. Theratechnologies is still waiting for the FDA decision on tesamorelin after the unanimous recommendation from an advisory committee. Bioniche’s parter Endo is expected to both release results from the first Phase 3 study of Urocidin™ and also start the second Phase 3 trial.

Evolution at Valeant and Angiotech

Two large companies continue to evolve. Valeant is slowly exiting from the NCE business and going back to its specialty pharma roots as it gives back clinical programs which were acquired by the prior Biovail management. Angiotech has announced a major debt restructuring which will cut its ongoing financing costs but will also result in major dilution for current common shareholders.

More to Come on Profitable Canadian Healthcare Companies

My focus as a biotech analyst over the years has been the development stage companies. The Canadian healthcare sector also includes numerous companies which are not only profitable but also do monthly distributions to shareholders. I will take a look at these companies in a future post.

Monday Biotech Deal Review: October 25, 2010

Welcome to your weekly review of Canadian biotech deals for October 25, 2010.  Last week’s notable transactions included the Qualifying Transaction of TSXV CPC company CCS Capital Inc. (now known as China Health Labs & Diagnostics Ltd.) and ProMetic’s strategic agreement with Allist Pharmaceuticals Inc., for the commercialization in China of two of ProMetic’s drug candidates.  Read on to learn more about these transactions, as well as the usual assortment of Canadian biotech news. Read more of this post

Monday Biotech Deal Review: February 22, 2010

There was a lot of follow-up among Canadian biotech deals this week: letters of intent turning into definitive agreements, merged companies turning to consolidation, bids launched on schedule and wrapped up; as well as an average crop of new M&Eh and securities.  Start things off with an interesting (cross-border!) twist to the SIFT/SR&ED deals we’ve seen after the jump…

Monday Biotech Deal Review: October 18, 2009

B&W_BigNickelThis week’s deal review has a big bought deal for IMRIS (and RBC), the details of Cardiome’s successful offer, and some follow-through for MethylGene and BioSyntech.  Read more of this post

Next Steps for Cardiome: activated Protein C Program will Seek Other Funding

Update: Cardiome extended its tender offer to allow time to digest the announcement below. Expiry is now October 13th.

When Cardiome (NASDAQ: CRME) (TSX: COM) announced its $27.5 million share buy-back program, the In Vivo Blog noted an earlier comment from its CEO, Doug Janzen, saying that Cardiome doesn’t “believe in the risks of building [its] own pipeline at this point.”

Well, it appears he meant it.  Cardiome has been developing its GED-aPC program via a subsidiary company, but has now decided that the drug “will be funded externally from Cardiome.”  The idea is that

“next steps for the program will be focused on finding external investors and/or partners to assist in future development of the asset.”

Also, Dr. Charles Fisher, CMO and EVP, Clinical & Regulatory Affairs, will be leaving the company and continuing as “a consultant to Cardiome.”

GED-aPC is a recombinant human activated Protein C (aPC) analog with a “broad” range of potential uses.

Bookmark and Share

Monday Biotech Deal Review: September 14, 2009

B&W_BigNickelThe Monday Deal Review is back in full force this week following a Labo(u)r Day vacation last week and there’s plenty of news including more information on the MDS-Danaher transaction and plenty of other companies finding ways to raise money and keep the lights on.  Keep reading after the jump…

Monday Deal Review: August 31, 2009

B&W_BigNickelThis week Canada seems to have accounted for a significant chunk of the Western Hemisphere’s biopharma deal activity … by numbers, anyway. By dollars, all is dwarfed by the $3.1 billion Proctor & Gamble/Warner Chilcott deal, but don’t let that stop you from reading on after the jump…

Monday Deal Review: August 3, 2009

B&W_BigNickelHopefully, the Deal Review will be a longer list as the newly-launched Ontario Emerging Technologies Fund starts deploying some capital, but for this week, the Canadian deal front was pretty quiet.   A few developments, like the JLL-Patheon pathos and the milestone for Cardiome from Merck, were noted at the time in our Twitter stream @crossborderbio, and aside from that there are only a few deals, and a bit of bad news, to check out  after the jump…

Monday Deal Review: May 25, 2009

bignickel1This week’s deal review has a couple of new placements, a couple of new plants, a very interesting claim asserted in Boston, and many, many updates on deals we have previously covered.  Check out the full review after the jump…

Cardiome Licenses Vernakalant (Oral) to Merck

Merck & Co., Inc. and Cardiome Pharma Corp. announced a collaboration and license agreement that provides Merck with exclusive global rights to the oral formulation of vernakalant for the maintenance of normal heart rhythm in patients with atrial fibrillation.

Here’s the deal:

  • US$60 million upfront
  • up to US$200 million in development and approval milestones
  • up to US$100 million for approval and subsequent indication milestones
  • tiered royalty payments
  • and up to US$340 million in sales threshold milestone payments
  • Cardiome retains a U.S. co-promotion right
  • Merck will be responsible for all future costs associated with the development, manufacturing and commercialization
  • Merck has granted Cardiome a secured, interest-bearing credit facility of up to US$100 million that Cardiome may access in tranches over several years commencing in 2010.

Cardiome and Astellas Pharma U.S., Inc. have a deal for vernakalant (IV) in the United States, Canada and Mexico; and this deal provides a Merck affiliate, Merck Sharp & Dohme (Switzerland) GmbH, with exclusive rights to the IV formulation outside of the United States, Canada and Mexico.

Effectiveness is subject to the HSR clearance, as well as other customary closing conditions.

Bookmark and Share

Follow

Get every new post delivered to your Inbox.

Join 131 other followers